CA2249368A1 - Administration of polypeptide growth factors following central nervous system ischemia or trauma - Google Patents

Administration of polypeptide growth factors following central nervous system ischemia or trauma Download PDF

Info

Publication number
CA2249368A1
CA2249368A1 CA002249368A CA2249368A CA2249368A1 CA 2249368 A1 CA2249368 A1 CA 2249368A1 CA 002249368 A CA002249368 A CA 002249368A CA 2249368 A CA2249368 A CA 2249368A CA 2249368 A1 CA2249368 A1 CA 2249368A1
Authority
CA
Canada
Prior art keywords
administration
growth factor
bfgf
animals
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002249368A
Other languages
English (en)
French (fr)
Inventor
Seth P. Finklestein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24485972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2249368(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2249368A1 publication Critical patent/CA2249368A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of Electric Motors In General (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Protection Of Generators And Motors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002249368A 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma Abandoned CA2249368A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
US08/620,444 1996-03-22

Publications (1)

Publication Number Publication Date
CA2249368A1 true CA2249368A1 (en) 1997-09-25

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002249368A Abandoned CA2249368A1 (en) 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma
CA2249596A Expired - Fee Related CA2249596C (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2249596A Expired - Fee Related CA2249596C (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Country Status (11)

Country Link
US (4) US6407060B1 (cg-RX-API-DMAC10.html)
EP (3) EP1364655B1 (cg-RX-API-DMAC10.html)
JP (2) JP4847634B2 (cg-RX-API-DMAC10.html)
KR (1) KR20000064752A (cg-RX-API-DMAC10.html)
CN (1) CN1181885C (cg-RX-API-DMAC10.html)
AT (2) ATE493141T1 (cg-RX-API-DMAC10.html)
AU (2) AU734312B2 (cg-RX-API-DMAC10.html)
CA (2) CA2249368A1 (cg-RX-API-DMAC10.html)
DE (2) DE69740089D1 (cg-RX-API-DMAC10.html)
ES (1) ES2201287T5 (cg-RX-API-DMAC10.html)
WO (2) WO1997034618A1 (cg-RX-API-DMAC10.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
PT1378572E (pt) 1993-05-12 2007-01-31 Genetics Inst Composições de bmp-11
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues
JP5033276B2 (ja) * 1997-05-05 2012-09-26 ストライカー コーポレイション 急性腎不全の治療
AU742663B2 (en) * 1997-05-30 2002-01-10 Stryker Corporation Methods for evaluating tissue morphogenesis and activity
CA2314423A1 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
WO2001012236A2 (en) * 1999-08-18 2001-02-22 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
ES2225241T3 (es) 1999-10-15 2005-03-16 Genetics Institute, Llc Formulaciones de acido hialuronico para suministrar proteinas osteogenicas.
US7060676B2 (en) 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
EP1289540B1 (en) 2000-06-01 2012-03-07 Children's Medical Center Corporation Oncomodulin for treating neurological disorders
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
EP1399023B1 (en) 2001-06-01 2008-04-30 Wyeth COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9;
KR20040048379A (ko) * 2001-06-01 2004-06-09 싸이트 테라피스 인코포레이티드 Ｔ 세포 유도된 조직 복구 및 재생
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
JP2006524991A (ja) 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド 抗原特異的ｔ細胞の作製および単離の方法
JP4971149B2 (ja) 2004-06-17 2012-07-11 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
DK2453024T3 (en) 2004-06-21 2018-02-12 Univ Leland Stanford Junior Genes and conduits that are differentially expressed in bipolar disorder and / or major depressive disorder
US20080108547A1 (en) * 2004-07-20 2008-05-08 Taylor Ii Larry Edmund Protease Inhibitor
US20090082263A1 (en) * 2004-07-29 2009-03-26 Anges, Mg, Inc. Drug and method for improving brain function
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
AU2006292147B2 (en) 2005-09-20 2013-03-07 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US20100047299A1 (en) * 2007-01-25 2010-02-25 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdf-5 for the improvement or maintenance of dermal appearance
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
JP5599778B2 (ja) * 2008-04-14 2014-10-01 デピュイ・シンセス・プロダクツ・エルエルシー 液体緩衝ｇｄｆ−５製剤
JP5819734B2 (ja) * 2009-02-12 2015-11-24 ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ ＴＧＦ−βスーパーファミリーメンバー含有タンパク質の最小に侵襲性の全身送達のための組成物および方法
SG173632A1 (en) * 2009-02-12 2011-09-29 Stryker Corp Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
JP5749659B2 (ja) 2009-03-12 2015-07-15 ハーゼ インベストメンツ ウーゲー Ｂｍｐアンタゴニスト感受性が低下した骨形成タンパク質２（ｂｍｐ２）変異体
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
AU2010341565A1 (en) 2009-12-22 2012-07-12 Stryker Corporation BMP-7 variants with reduced immunogenicity
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CA2807343C (en) 2010-08-20 2018-05-22 Wyeth Llc Designer osteogenic proteins
CA2829006A1 (en) * 2011-03-04 2012-09-13 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
HK1198333A1 (zh) * 2011-07-19 2015-04-02 Thrasos Innovation, Inc. 抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP3816625B1 (en) 2013-05-06 2025-09-17 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3007719B1 (en) * 2013-06-11 2021-03-17 President and Fellows of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
EP4406585A3 (en) 2015-02-13 2024-10-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
MX2021000157A (es) * 2018-07-03 2021-12-10 Venturis Therapeutics Inc Composiciones y métodos para tratar el derrame cerebral.
US20230095167A1 (en) * 2020-02-20 2023-03-30 Universiteit Maastricht Detection method of circulating bmp10 (bone morphogenetic protein 10)
AU2021273813A1 (en) * 2020-05-19 2023-02-02 Elevian, Inc. Methods and compositions for treating stroke
WO2024259004A1 (en) * 2023-06-13 2024-12-19 Bedford Research Foundation Systems and methods of cell transport at ambient temperature

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4861757A (en) 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
FI910081A0 (fi) 1988-07-08 1991-01-07 Univ London Analys av cellmodifierande substanser.
AU4056089A (en) 1988-07-20 1990-02-19 Amgen, Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
EP0448704B1 (en) 1989-10-17 1998-06-17 Stryker Corporation Osteogenic devices
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
WO1992000382A1 (en) 1990-06-15 1992-01-09 Carnegie Institution Of Washington Gdf-1
EP0550625B1 (en) 1990-09-26 2003-11-05 Genetics Institute, LLC Bmp-5 derivatives
AU663689B2 (en) 1990-10-18 1995-10-19 Stryker Corporation Osteogenic peptides
CA2096441A1 (en) 1990-11-16 1992-05-17 Celtrix Pharmaceuticals, Inc. Heterodimer of b-type transforming growth factors 2 and 3
ATE212554T1 (de) 1990-11-27 2002-02-15 American Nat Red Cross Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
AU651421B2 (en) 1990-11-30 1994-07-21 Celtrix Pharmaceuticals, Inc. Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair
JP3627985B2 (ja) 1991-03-11 2005-03-09 キュリス インコーポレイテッド タンパク質により誘導される形態形成
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
WO1992020371A1 (en) 1991-05-10 1992-11-26 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
JPH06500574A (ja) 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
ES2094359T3 (es) 1991-06-21 1997-01-16 Genetics Inst Formulaciones farmaceuticas de proteinas osteogenicas.
AU652472B2 (en) 1991-06-25 1994-08-25 Genetics Institute, Llc BMP-9 compositions
EP0601129B1 (en) 1991-08-30 2000-11-15 Creative Biomolecules, Inc. Morphogenic protein screening method
ES2149776T5 (es) 1991-08-30 2004-07-01 Curis, Inc. Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
EP1637156A1 (en) 1991-08-30 2006-03-22 Curis, Inc. Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases
AU674500B2 (en) 1991-11-04 1997-01-02 Genetics Institute, Llc Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
ATE178801T1 (de) * 1991-11-22 1999-04-15 Genentech Inc Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
DK0653942T3 (da) * 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
KR100329409B1 (ko) 1993-08-26 2002-03-20 브루스 엠. 에이센, 토마스 제이 데스로저 인간 골 형태발생 단백질을 사용한 신경 재생법
AU7605394A (en) 1993-09-03 1995-03-22 Regents Of The University Of California, The Neural tissue affecting factor and compositions
CA2174098C (en) 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues

Also Published As

Publication number Publication date
EP0894004A1 (en) 1999-02-03
WO1997034618A1 (en) 1997-09-25
US20010039261A1 (en) 2001-11-08
AU734312B2 (en) 2001-06-07
JP2000507939A (ja) 2000-06-27
ES2201287T5 (es) 2007-10-16
CN1181885C (zh) 2004-12-29
EP0894004B1 (en) 2003-07-09
AU2552997A (en) 1997-10-10
DE69723429T2 (de) 2004-04-22
WO1997034626A1 (en) 1997-09-25
ES2201287T3 (es) 2004-03-16
KR20000064752A (ko) 2000-11-06
EP0904093A1 (en) 1999-03-31
EP1364655B1 (en) 2010-12-29
US6214796B1 (en) 2001-04-10
EP1364655A1 (en) 2003-11-26
US6407060B1 (en) 2002-06-18
ATE493141T1 (de) 2011-01-15
CN1219133A (zh) 1999-06-09
DE69723429D1 (de) 2003-08-14
CA2249596C (en) 2011-11-08
CA2249596A1 (en) 1997-09-25
DE69740089D1 (de) 2011-02-10
ATE244574T1 (de) 2003-07-15
DE69723429T3 (de) 2007-09-20
EP0894004B2 (en) 2007-02-21
JP4847634B2 (ja) 2011-12-28
JP2000506894A (ja) 2000-06-06
EP0904093A4 (en) 2004-11-17
US20030022830A1 (en) 2003-01-30
AU2582397A (en) 1997-10-10
AU725341B2 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
US6214796B1 (en) Administration of polypeptide growth factors following central nervous system ischemia or trauma
KR100341193B1 (ko) 신경 생육인자 약학 배합물
WO1993008828A1 (en) Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
US7304029B1 (en) Neuroprotective effect of growth hormone
WO1993009802A2 (en) Tgf-beta to improve neural outcome
EP0862452B1 (en) Stabilizing formulation for ngf
CN116917482A (zh) 嵌合蛋白和治疗中枢神经系统疾病的方法
CA2516857A1 (en) Use of intraputaminal infused glial cell-line derived neurotrophic factor in the treatment of parkinson's disease in humans
BR112020000115A2 (pt) sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
US6090781A (en) Stabilizing formulation for NGF
SK2694A3 (en) Pharmaceutical agent for treatment of motor neuron diseases
TWI327473B (en) Composition for treating a cerebrovascular disease and a method for increasing expression of erythropoietin
JP2001504123A (ja) Ｃｎｓ障害に対して保護するための成長因子を用いた予備治療
EP1100523A1 (en) Treatment of central nervous system ischemia or trauma with epidermal growth factor-like polypeptides
AU9676598A (en) Apolipoprotein e/growth factor complexes and methods of use
US6964947B1 (en) Stabilizing formulation for NGF
US9023799B2 (en) Method to reduce loss of cardiac function following ischemia/reperfusion
CA2619721A1 (en) Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
WO2000033864A1 (fr) Remedes contre les defaillances tactiles
HK1015261B (en) Stabilizing formulation for ngf

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued